Clinical trials located in

Reading

Reading city is located in United Kingdom. Currently, 9 clinical trials are being conducted in this city.

Reading, located in the Thames Valley in southern England, is a city steeped in history and modernity. It is renowned for the Reading Festival, one of the UK’s most famous music festivals. The city’s origins date back to the 8th century, and it played a significant role in the English Civil War. Reading Abbey, a historical site founded by Henry I in 1121, is among its notable landmarks. The city is also a hub for technology and business, often referred to as the Silicon Valley of the UK. Additionally, Reading was the residence of the famous Victorian novelist Jane Austen.

  • CT-EU-00116351

    Comparing ruxolitinib, hydroxycarbamide, and Interferon as first-line treatments for high-risk Polycythemia Vera

    The study, known as MITHRIDATE, investigates the effectiveness of the drug Ruxolitinib compared to either Hydroxycarbamide or Interferon Alpha for patients with high-risk Polycythemia Vera, a type of blood disorder. This Phase III clinical trial aims to determine which treatment is more effective in managing the disease without leading to additional health complications.

    Patients in the trial are assigned to receive either Ruxolitinib or the best available therapy, chosen from Hydroxycarbamide or Interferon Alpha, as decided by the overseeing doctors. The course of the study involves regular monitoring and assessments to evaluate the impact of these treatments on the disease’s progression and patients’ overall health and quality of life. The study is conducted in a controlled environment to ensure reliable results.

    • Interferon-Alpha
    • Hydroxycarbamide
    • Ruxolitinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Radium-223 radiation vs. new hormone therapy in prostate cancer trial

    In this study, scientists are looking into two treatments for prostate cancer that has spread to the bone. One is a medicine called Radium-223 Dichloride or simply Xofigo which uses radiation to destroy cancer cells. The other is a new kind of treatment that stops hormones from working, as these hormones can sometimes help cancer grow. This new treatment is called Novel Anti-hormonal Therapy or NAH for short. The aim is to see which works better and to compare their safety profiles. Xofigo works by emitting a special type of radiation once it is injected into the body and absorbed by the bones. This radiation travels only a short distance, so it doesn’t harm healthy cells while killing cancerous ones. NAH, on the other hand, includes medications like abiraterone acetate (Zytiga) or enzalutamide (Xtandi) which are usually given to advanced prostate cancer patients. People taking part in this study will either receive Xofigo or NAH. Xofigo is given via an injection into a vein every 4 weeks for up to 6 months, while an oral form of NAH will be given daily until the disease progresses. Participants will be in this study for around 2 years, visiting the hospital or clinic every 2 weeks initially and then less often. There will be blood and urine tests and questionnaires about well-being and pain management.

    • Radium-223 dichloride/BAY88-8223
    • enzalutamide
    • prednisolone
    • abiraterone acetate
  • Evaluating itch relief in liver disease with linerixibat

    The GLISTEN study is a detailed research project exploring the effectiveness of a medication called linerixibat in treating severe itching in people with a liver condition known as Primary Biliary Cholangitis (PBC). In this study, participants are given either linerixibat or a placebo to see which one better reduces itching and improves sleep and overall quality of life. This research is important for finding new ways to help people with PBC who experience discomfort from itching.

    • Linerixibat
  • Safety and tolerance test of linerixibat for cholestatic pruritus

    The aim of this study is to find out how safe and effective long-term treatment with a drug called linerixibat is in people with primary biliary cholangitis (PBC). PBC is a disease in which bile, which helps digest food, cannot flow properly, causing the skin to become itchy. This study will include people who have already taken linerixibat in previous studies. The study continues until the end or until the drug can legally be administered to patients, depending on how long the patient stays at the facility. Scientists will check for side effects and monitor the patient’s quality of life using questionnaires. These surveys will cover any symptoms, itching, fatigue, mental clarity, social and emotional life. Another questionnaire assesses whether the patient’s health affects his or her daily activities and feelings.

    • Linerixibat
  • Assessing the efficacy of atuliflapon in uncontrolled asthma relief

    This study is looking at atuliflapon, a new medication, for adults with moderate to severe uncontrolled asthma. The trial is a Phase 2 study, which means it’s testing how effective and safe atuliflapon is. About 1,102 adults who are already using asthma medications will be part of this study. They will take atuliflapon or a placebo once a day for 12 weeks. The goal is to see if atuliflapon can help reduce asthma attacks and improve breathing in people whose asthma isn’t well-controlled with their current treatments.

    • Atuliflapon
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom:

.